Most of the retatrutide coverage this year has been about the number on the scales. But the more interesting story in the phase 3 data is a side effect that barely registered in phase 2 and then turned up repeatedly across the TRIUMPH programme — and the Australian machinery that would be responsible for catching things like it if retatrutide is ever registered here.

This post looks at retatrutide side effects as reported in the phase 3 trials, and at one specifically Australian consequence: the TGA's black triangle scheme, which a 2026 study found almost nobody in this country recognises.

Retatrutide side effects: what TRIUMPH-1 actually reported

TRIUMPH-1 randomised 2,339 adults with obesity or overweight 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg or placebo over 80 weeks. Lilly reported mean weight loss of 19.0%, 25.9% and 28.3% across the three doses versus 2.2% on placebo, with 45.3% of the 12 mg group losing at least 30% of body weight. A prespecified extension in participants with BMI ≥35 reached 30.3% at 104 weeks.

On tolerability, Lilly's release described the safety profile as generally consistent with the incretin class — nausea, diarrhoea, constipation and vomiting as the most common events, mostly mild to moderate. Trade coverage of the readout put the 12 mg rates at roughly 42% nausea, 32% diarrhoea, 26% constipation and 25% vomiting.

The number worth sitting with is discontinuation. Adverse-event discontinuations ran 4.1%, 6.9% and 11.3% on 4 mg, 9 mg and 12 mg, against 4.9% on placebo. In other words, the dose producing the headline 28.3% is also the dose where roughly one in nine people stopped because of side effects — while at 4 mg, discontinuation was no higher than placebo. That trade-off is the whole clinical conversation, and it's one reason dose flexibility matters more than any single headline figure. More on the programme structure is in our clinical trials overview.

The signal that wasn't obvious in phase 2

The non-gastrointestinal finding that has drawn attention is dysesthesia — an altered, tingling or unpleasant skin sensation. In TRIUMPH-1, coverage of the 12 mg arm reported roughly 12.5% versus 0.9% on placebo. In the later TRIUMPH readouts, BioSpace reported 8.8% at 9 mg and 20.9% at 12 mg against 0.7% on placebo, and characterised it as a new signal that had not been reported in Lilly's mid-stage trial.

Two honest caveats. First, Lilly said the events generally did not lead to discontinuation and that most resolved during treatment. Second, these percentages are drawn from company announcements and press coverage, not from full peer-reviewed publications of each trial's safety tables — the TRIUMPH registrational design paper is published in Diabetes, Obesity and Metabolism, but the detailed outcome papers are the documents that will settle the exact figures. Treat the numbers as directionally reliable and precisely provisional. Press coverage also notes dose-dependent heart-rate increases that peaked around week 24 and then declined, consistent with the class.

The broader point stands regardless of the decimal places: a side effect that was not a headline issue in a 338-person phase 2 trial became a consistent, dose-related finding once thousands of people were dosed for longer. That is exactly what larger and longer trials are for — and exactly why post-approval monitoring exists, because phase 3 is not the last word either. Our safety page tracks this as the data matures.

Why this matters in Australia: the black triangle

Retatrutide is investigational and not approved by the TGA. Lilly has indicated it plans to begin regulatory filings from 2027, so nothing here is a prescribing decision for anyone in Australia today. But it does tell you something about what would happen next.

Australia's Black Triangle Scheme, launched in January 2018 and modelled on similar European and UK programmes, places a small black triangle on the product information and consumer medicine information for new prescription medicines when they're registered, and for older medicines approved for new uses. The triangle doesn't mean a medicine is unsafe. It means it's under closer watch, and it's a prompt for patients and health professionals to report any suspected side effects to the TGA, which feeds them into the Database of Adverse Event Notifications. For provisionally registered medicines, the symbol stays for at least five years.

Any brand-new obesity drug arriving in Australia would enter that system. Which makes a June 2026 finding awkward: a University of Adelaide-led study published in the British Journal of Clinical Pharmacology, reported by the ABC, found more than 90% of consumers and around half of health professionals could not correctly identify the black triangle symbol. Researchers suggested larger symbols or stickers on packaging and targeted training for clinicians.

The practical Australian implication is simple. If a drug like retatrutide were registered here carrying a novel, dose-related side effect such as dysesthesia, the speed at which real-world patterns emerge depends on Australians actually reporting what they experience — and you can't act on a prompt you don't recognise. Anyone in Australia can report a suspected side effect to the TGA directly; you don't need to go through a doctor to do it. More Australian context is on our Australia page.

What this changes for how you read weight-loss headlines

If you're following retatrutide, the useful habit is to read efficacy and tolerability from the same dose column. A 28.3% average and an 11.3% adverse-event discontinuation rate describe the same 12 mg group. A 19.0% average and a placebo-level discontinuation rate describe the same 4 mg group. Both are true; neither is the whole drug. For the mechanism behind why a triple agonist behaves differently from a single- or dual-receptor drug, see what is retatrutide.

Want the phase 3 safety papers and any TGA movement as it lands? Join the free updates list.

FAQ

What are the most common retatrutide side effects?

Across phase 3, the most common were gastrointestinal — nausea, diarrhoea, constipation and vomiting — generally mild to moderate and most common during dose escalation. Coverage of TRIUMPH-1's 12 mg arm reported roughly 42% nausea, 32% diarrhoea, 26% constipation and 25% vomiting.

What is dysesthesia and does retatrutide cause it?

Dysesthesia is an altered, tingling or unpleasant skin sensation. It was reported far more often on retatrutide than placebo in phase 3 — around 12.5% at 12 mg versus 0.9% on placebo in TRIUMPH-1, and up to 20.9% at 12 mg in later readouts — but Lilly said the events generally did not cause people to stop treatment and most resolved during the trial.

Is retatrutide approved in Australia?

No. Retatrutide is investigational and has not been approved by the TGA. Lilly has indicated it plans to begin regulatory filings from 2027, and approval in any jurisdiction is not guaranteed.

How do I report a medicine side effect in Australia?

You can report suspected side effects directly to the TGA, which stores them in the Database of Adverse Event Notifications for safety analysis. New prescription medicines carry a black triangle on their product and consumer medicine information as a reminder to do exactly that.

Sources

This article is for general information only and is not medical advice. Retatrutide is an investigational medicine that is not approved by the TGA or available on prescription in Australia. Speak to a qualified Australian health professional about your own circumstances. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.